A nano-hydroxyapatite/carboxymethyl chitosan/polylactic-glycolic acid micro-nano hybrid drug-loaded scaffold and its bionic preparation method

A technology of nano-hydroxyapatite and carboxymethyl chitosan, applied in tissue regeneration, medical science, prosthesis, etc., can solve the problem of poor hydrophilicity and biocompatibility, lack of cell recognizable sites, lack of Biological activity and other issues, to achieve the effect of improving biological activity, good biocompatibility, and realizing complementary functional advantages

Active Publication Date: 2019-07-09
FUZHOU UNIV
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, such materials also have disadvantages such as poor hydrophilicity and biocompatibility, lack of cell-recognizable sites, degradation products may cause aseptic inflammation, and generally have no biological activity. It is necessary to combine nano-hydroxyapatite and Carboxymethyl chitosan improves the defects of various materials and realizes the optimization of the performance of biological porous scaffolds

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A nano-hydroxyapatite/carboxymethyl chitosan/polylactic-glycolic acid micro-nano hybrid drug-loaded scaffold and its bionic preparation method
  • A nano-hydroxyapatite/carboxymethyl chitosan/polylactic-glycolic acid micro-nano hybrid drug-loaded scaffold and its bionic preparation method
  • A nano-hydroxyapatite/carboxymethyl chitosan/polylactic-glycolic acid micro-nano hybrid drug-loaded scaffold and its bionic preparation method

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0040] 1) Disperse 0.075g of nano-hydroxyapatite in 20mL of deionized water, and sonicate for 10min to make it evenly dispersed;

[0041] 2) Add 0.2g carboxymethyl chitosan to it, and stir with a magnetic stirrer for 1h to form a uniform water phase (continuous phase);

[0042] 3) Take 136 µg icariin and add it to the above aqueous phase to prepare a molar concentration of 10 -5 M's icariin solution;

[0043] 4) Dissolve 0.32g of polylactic glycolic acid in 8mL of dichloromethane to prepare the oil phase (dispersed phase) of the emulsion;

[0044] 5) Take 5mL of the emulsion water phase and 2mL of the oil phase, add them to the mold, and add 14.5 µL of glutaraldehyde to it with the molar ratio of amino groups and aldehyde groups at 1:1, and use the Ultra Turrax T25 high-speed emulsifier at 15×10 3 Emulsify at rpm / min, emulsification time is 1min;

[0045] 6) Place the emulsion at room temperature for 12 hours to evaporate the solvent, then transfer it to -10~-80°C and freez...

Embodiment 2

[0047] 1) Disperse 0.15g of nano-hydroxyapatite in 20mL of deionized water, and sonicate for 10min to make it evenly dispersed;

[0048] 2) Add 0.2g carboxymethyl chitosan to it, and stir with a magnetic stirrer for 1h to form a uniform water phase (continuous phase);

[0049] 3) Take 136µg icariin and add it to the above aqueous phase to prepare a molar concentration of 10 -5 M's icariin solution;

[0050] 4) Dissolve 0.32g of polylactic-glycolic acid in 8mL of dichloromethane to prepare the oil phase (dispersed phase) of the emulsion;

[0051] 5) Take 5mL of the emulsion water phase and 2mL of the oil phase, put them into the mold, and add 14.5 µL of glutaraldehyde to it with the molar ratio of amino group and aldehyde group at 1:1, and use the Ultra Turrax T25 high-speed emulsifier at 15×10 3 Emulsify at rpm / min, emulsification time is 1min;

[0052] 6) Place the emulsion at room temperature for 12 hours to evaporate the solvent, then transfer it to -10~-80°C and freeze ...

Embodiment 3

[0054] 1) Disperse 0.3g of nano-hydroxyapatite in 20mL of deionized water, and sonicate for 10min to make it evenly dispersed;

[0055] 2) Add 0.2g carboxymethyl chitosan to it, and stir with a magnetic stirrer for 1h to form a uniform water phase (continuous phase);

[0056] 3) Take 136µg icariin and add it to the above aqueous phase to prepare a molar concentration of 10 -5 M's icariin solution;

[0057] 4) Dissolve 0.32g of polylactic-glycolic acid in 8mL of dichloromethane to prepare the oil phase (dispersed phase) of the emulsion;

[0058] 5) Take 5mL of the emulsion water phase and 2mL of the oil phase, put them into the mold, and add 14.5 µL of glutaraldehyde to it with the molar ratio of amino group and aldehyde group at 1:1, and use the Ultra Turrax T25 high-speed emulsifier at 15×10 3 Emulsify at rpm / min, emulsification time is 1min;

[0059] 6) Place the emulsion at room temperature for 12 hours to evaporate the solvent, then transfer it to -10~-80°C and freeze i...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the field of composite materials, and concretely relates to a nano-hydroxyapatite / carboxymethyl chitosan / poly(lactic-co-glycolic acid) micro-nano hybrid drug-loaded scaffold and a bionic preparation method thereof. The three-dimensional bionic hybrid drug-loaded scaffold is prepared through combining solvent evaporation and freeze drying technologies by using a high speed emulsifying machine via adopting nano-hydroxyapatite and carboxymethyl chitosan as a water phase and an emulsion continuous phase, adopting a methylene chloride solution of poly(lactic-co-glycolic acid) as an oil phase and an emulsion dispersion phase, using glutaraldehyde as a cross-linking agent to immobilize the carboxymethyl chitosan in the continuous phase and adopting the main component icariin in a traditional Chinese medicine epimeddium as a carrier drug. The preparation method has the advantages of simple preparation process and mild reaction conditions, and the obtained scaffold overcomes the performance defects of single natural polymer materials or synthetic polymer materials, has the advantages of intercommunicated pores, uniform pore diameter, figurability, slow drug release, good bone bonding ability and good biocompatibility, and is expected to become a new osteoporosis treatment composite material.

Description

technical field [0001] The invention belongs to the field of composite materials, and in particular relates to a nano-hydroxyapatite / carboxymethyl chitosan / polylactic acid glycolic acid micro-nano hybrid drug-loaded support and a bionic preparation method thereof. Background technique [0002] In recent years, with the extension of life expectancy and the aggravation of population aging, osteoporosis has become one of the important diseases affecting human health. Osteoporosis is a series of skeletal lesions caused by various reasons. It is a systemic skeletal disease characterized by low bone mass per unit volume and destruction of bone tissue microstructure. Accompanied by the aggravation of bone loss, the bone density of patients gradually decreases. , Bone fragility increases, greatly increasing the probability of fractures in patients, and its clinical manifestations are bone pain and fractures. According to the estimates of the World Health Organization, about 200 mil...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61L27/48A61L27/42A61L27/54A61L27/56A61L27/58
CPCA61L27/425A61L27/48A61L27/54A61L27/56A61L27/58A61L2300/232A61L2300/412A61L2300/602A61L2430/02C08L5/08C08L67/04
Inventor 陈景帝胡义敏赵耀李倩张其清
Owner FUZHOU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products